On November 17, 2025, a pivotal study led by Dr. Jennifer Miller from Yale University highlighted an alarming realization concerning the accessibility of newly approved medicines in countries that have hosted clinical trials. Published in JAMA Internal Medicine, the study reveals that many of the countries that contributed to the testing of these FDA-approved medicines often remain without physical access to them, raising serious ethical concerns.

Overview of the Study

The researchers examined a total of 172 FDA-approved medicines tested in nearly 90 countries from 2015 to 2018. The data revealed that, five years after being tested, only 24% of these medicines had gained market authorization for distribution in the very countries where the clinical trials took place. A significant disparity was noted, where high-income countries experienced greater access to these medicines compared to their upper-middle- and lower-middle-income counterparts.

Ethical Implications

Dr. Miller emphasized the ethical implications related to this lack of access. According to her, when a population participates in clinical trials, they should benefit from the knowledge derived from those trials. This tenet of distributive justice is a hallmark of ethical guidelines such as:

  • The World Medical Association Declaration of Helsinki (1964)
  • The International Guidelines for Health-related Research Involving Humans, published by the Council for International Organizations of Medical Sciences (2016)

Despite these guidelines, they are often criticized for their ambiguity, which can allow organizations to bypass their intended purposes. Dr. Cary Gross, a co-author of the study and professor of medicine, noted, “While participants may enroll in trials to contribute to scientific progress, there is an unstated expectation that, if effective, the treatments will be accessible to their communities.”

Findings and Statistics

The study substantiated the idea that many countries endure the burden of hosting clinical trials without enjoying the benefits of the new medicines tested within their borders, potentially leading to context-specific health inequities. The following table summarizes the main findings of the study:

Category Percentage of Medicines with Market Authorization Income Level of Countries
High-Income Countries Approximately 50% High
Upper-Middle-Income Countries 20% Upper-Middle
Lower-Middle-Income Countries 12% Lower-Middle
Total across surveyed countries 24% All

Measures to Improve Access

In response to these findings, Dr. Miller plans to expand the Good Pharma Scorecard.

This scorecard is an index established to evaluate pharmaceutical companies based on their ethical performance, focusing on aspects such as data transparency and post-trial medicine access. Miller notes:

“The scorecard sets clear goals for the sector, tracks progress, and makes the results public. We aim to use this transparency as leverage to close the access gap.”

Insights from Successful Countries

Dr. Miller's team is also examining “bright spots” such as Ethiopia and Uganda, countries that successfully ensured full access to the medicines they helped to test. A collaborative initiative bringing health ministers and clinical trial leaders from these countries to share their strategies will be undertaken to disseminate their successful practices.

The Path Forward

Addressing the issue of trial-hosting countries lacking access to new medicines requires a collective effort. As Dr. Miller articulates:

  • Pharmaceutical companies must adopt transparent and ethical practices.
  • Countries need to be empowered and supported in policy-making to protect their interests.
  • Media, non-governmental organizations (NGOs), and patient associations should stay engaged to advocate for better outcomes.

To conclude, the disparity highlighted by this study calls for transformative changes within the pharmaceutical sector and healthcare policies globally, ensuring that the principle of equity is upheld for the benefit of all populations involved in clinical trials.

References

More information on this study can be found in the publication: Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals, JAMA Internal Medicine (2025).

For a detailed analysis, visit Medical Xpress.